Toxicology of micronutrients: Adverse effects and uncertainty

Journal of Nutrition

Volumn 136, Issue 2, 2006, Pages

  Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Micronutrient toxicity; Risk management; Upper intake levels

Indexed keywords

FOOD ADDITIVE; MINERAL; PESTICIDE; TRACE ELEMENT; VITAMIN;

CONFERENCE PAPER; DATA ANALYSIS; DIETARY INTAKE; FOOD ANALYSIS; FOOD POISONING; FOOD SAFETY; HUMAN; NONHUMAN; NUTRIENT CONTENT; ORGANIZATION; RISK ASSESSMENT;

EID: 32444441480     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.2.493s     Document Type: Conference Paper

References (82)

1. Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment. Annual report. London: Department of Health; 1997.
2. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academies Press; 1997. Available from: http://www.nap.edu/books/ 0309063507/html.
3. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academies Press; 1998. Available from: http://www.nap.edu/openbook/0309065542/html/.
4. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academies Press; 2000. Available from: http://www.nap.edu/openbook/ 0309069351/html/index.html.
5. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academies Press; 2001. Available from: http://www.nap.edu/books/ 0309072794/html/.
6. Scientific Committee for Food. European Commission. Outcome of discussions. Available from: http://europa.eu.int/comm/food/fs/sc/scf/ outcome_en.html.
7. Expert Group on Vitamins and Minerals. Safe upper levels for vitamins and minerals. London: Food Standards Agency of the United Kingdom; 2003.
8. Nordic Council of Ministers. Risk evaluation of essential trace elements - essential versus toxic levels of intake. Copenhagen: Nordic Council of Ministers; 1995.
9. International Programme on Chemical Safety. Principles and methods for the assessments of risk from essential trace elements. Geneva: World Health Organization; 1999.
10. Ministère de l'Économie et des Finances, Ministère du Travail et des Affaires Sociale, Ministère de l'Agriculture, de la Peche et de l'Alimentation. Rapport sur les limites de sécurité dans les consummations alimentaires des vitamins et minéraux. Paris: Ministère de l'Économie et des Finances, Ministère du Travail et des Affaires Sociale, Ministère de l'Agriculture, de la Peche et de l'Alimentation; 1995.
11. Council for Responsible Nutrition. Vitamin and mineral safety. Washington, DC: Council for Responsible Nutrition; 1997.
12. European Federation of Health Product Manufacturers Associations. Vitamins and minerals. a scientific evaluation of the range of safe intakes. Surrey, UK: The Council of Responsible Nutrition; 1997.
13. Consumers for Health Choice. A summary of the science of vitamin and mineral supplement safety. Brussels: Consumers for Health Choice; 1998.
14. Renwick AG. Exposure estimation, toxicological requirements and risk assessment. In: van der Heijden K, Younes M, Fishbein L, Miller S, editors. International food safety handbook. New York: Marcel Dekker; 1999. p. 59-94.
15. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
16. Beck BD, Conolly RB, Dourson ML, Guth D, Harris D, Kimmel C, Lewis SC. Improvements in quantitative noncancer risk assessment. Fundam Appl Toxicol. 1993;20:1-14.
17. International Programme on Chemical Safety. Assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits: Environmental Health Criteria no 170. Geneva: World Health Organization; 1994.
18. Vermeire T, Stevenson H, Peiters MN, Rennen M, Slob W, Hakkert BC. Assessment factors for human health risk assessment: a discussion paper. Crit Rev Toxicol. 1999;29:439-90.
19. World Health Organization. Principles for the safety assessment of food additives and contaminants in food: Environmental Health Criteria no. 70. Geneva: World Health Organization; 1987.
20. Dourson ML, Stara JF. Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol. 1983;3:224-8.
21. Calabrese EJ. Uncertainty factors and interindividual variation. Regul Toxicol Pharmacol. 1985;5:190-6.
22. Hattis D, Erdreich L, Ballew M. Human variability in susceptibility to toxic chemicals: a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 1987;7:415-26.
23. Renwick AG. Safety factors and the establishment of acceptable daily intakes. Food Addit Contam. 1991;8:135-50.
24. Renwick AG. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contam. 1993;10:275-305.
25. Calabrese EJ, Beck BD, Chappell WR. Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area? Regul Toxicol Pharmacol. 1992;15:172-9.
26. Naumann BD, Weideman PA. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum Ecol Risk Assess. 1995;1:590-613.
27. Dourson ML, Felter SP, Robinson D. Evolution of science-based uncertainty factors for noncancer risk assessment. Regul Toxicol Pharmacol. 1996;24:108-20.
28. Renwick AG, Lazarus NR. Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul Toxicol Pharmacol. 1998;27:3-20.
29. Silverman KC, Naumann BD, Holder DJ, Dixit R, Faria EC, Sargent EV, Gallo MA. Establishing data-derived adjustment factors from published pharmaceutical clinical trial data. Hum Ecol Risk Assess. 1999;5:1059-89.
30. World Health Organization, International Programme on Chemical Safety. Guidance document for the use of data in development of chemical-specific adjustment factors (CSAFs) for interspecies differences and human variability in dose/concentration-response assessment. Geneva: WHO; 2001. Available from: http://www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html.
31. Dorne JL, Walton K, Renwick AG. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem Toxicol. 2001;39:1153-73.
32. Dorne JL, Walton K, Slob W, Renwick AG. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol. 2002;40:1633-56.
33. Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors. Food Chem Toxicol. 2003;41:201-24.
34. Dorne JL, Walton K, Renwick AG. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem Toxicol. 2003;41:225-45.
35. Dorne JL, Walton K, Renwick AG. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem Toxicol. 2004;42:275-98.
36. Scientific Committee for Food. Reports of the Scientific Committee for Food: nutrient and energy intakes for the European Commission, thirty-first series. Brussels: European Commission; 1993. Available from: http://europa.eu.int/comm/food/fs/sc/scf/reports/scf_reports_31.pdf.
37. Biesalski HK. Comparative assessment of the toxicology of vitamin A and retinoids in man. Toxicology. 1989;57:117-61.
38. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med. 1995;333:1369-73.
39. Miller RK, Hendricks AG, Mills JL, Hummler H, Wiegand UW. Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol. 1998;12:75-88.
40. Buss NE, Tembe EA, Prendergast BD, Renwick AG, George CF. The teratogenic metabolites of vitamin A in women following supplements and liver. Hum Exp Toxicol. 1994;13:33-43.
41. Tembe EA, Honeywell R, Buss NE, Renwick AG. All-trans-retinoic acid in maternal plasma and teratogenicity in rats and rabbits. Toxicol Appl Pharmacol. 1996;141:456-72.
42. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the tolerable upper intake level of preformed vitamin A (retinol and retinyl esters). Brussels: European Commission; 2002. Available from: http://europa.eu.int/comm/food/fs/sc/scf/out145_en.pdf.
43. Freudenheim JL, Johnson NE, Smith EL. Relationship between usual nutrient intake and bone-mineral content of women 35-65 years of age: longitudinal and cross-sectional analysis. Am J Clin Nutr. 1986;44:863-76.
44. Houtkooper LB, Ritenbaugh C, Aickin M, Lohman TG, Going SB, Weber JL, Greaves KA, Boyden TW, Pamenter RW, Hall MC. Nutrients, body composition and exercise are related to change in bone mineral density in pre-menopausal women. J Nutr. 1995;125:1229-37.
45. Melhus H, Michaelsson K, Kindmark A, Bergstrom R, Holmberg L, Mallmin H, Wolk A, Ljunghall S. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk of hip fracture. Ann Intern Med. 1998;129:770-8.
46. Ballew C, Galuska D, Gillespie C. High serum retinyl esters are not associated with reduced bone mineral density in the Third National Health and Nutrition Examination Survey, 1988-1994. J Bone Miner Res. 2001;16:2306-12.
47. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
48. Promislow JH, Goodman-Gruen D, Slymen DJ, Barret-Connor E. Retinol intake and bone mineral density in the elderly: the Rancho Bernado Study. J Bone Miner Res. 2002;17:1349-58.
49. Woutersen RA, Wolterbeek APM, Appel MJ, van den Berg H, Goldbohm RA, Feron VJ. Safety evaluation of synthetic β-carotene. Crit Rev Toxicol. 1999;29:515-42.
50. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russel RM. Retinoid signalling and activator protein 1 expression in ferrets given b-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst. 1999;91:60-6.
51. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the tolerable upper intake level of beta carotene. Brussels: European Commission; 2000. Available from: http://europa.eu.int/comm/food/fs/sc/scf/ out80b_en.pdf.
52. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309:445-8.
53. Berger A, Schaumburg HH. More on neuropathy from pyridoxine abuse. N Engl J Med. 1984;311:986-7.
54. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466-8.
55. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy. Neurology. 1992;42:1367-70.
56. Bernstein AL. Vitamin B6 in clinical neurology. Ann N Y Acad Sci. 1990;585:250-60.
57. Bernstein AL, Lobitz CS. A clinical and electrophysiologic study of the treatment of painful diabetic neuropathies with pyridoxine. In:Leklem J, Reynolds RD, editors. Clinical and physiological applications of vitamin B-6. New York: Alan R. Liss, Inc.; 1988. p. 415-23.
58. Brush MG. Vitamin B-6 treatment of premenstrual syndrome. In: Leklem J, Reynolds RD, editors. Clinical and physiological applications of vitamin B-6. New York: Alan R. Liss, Inc.; 1988. p. 363-79.
59. Brush MG, Perry M. Pyridoxine and the premenstrual syndrome. Lancet. 1985;(8442)1:1399.
60. Brush MG, Bennett T, Hansen K. Pyridoxine in the treatment of premenstrual syndrome: a retrospective survey in 630 patients. Br J Clin Pract. 1988;42:448-52.
61. Kerr GD. The management of premenstrual syndrome. Curr Med Res Opin. 1977;4:29-34.
62. Day JB. Clinical trials in the premenstrual syndrome. Curr Med Res Opin. 1979;6: suppl 5:40-5.
63. Williams MJ, Harris RI, Dean BC. Controlled trial of pyridoxine in the premenstrual syndrome. J Int Med Res. 1985;13:174-9.
64. Dalton K, Dalton MJT. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987;76:8-11.
65. Del Tredici AM, Bernstein AL, Chinn K. Carpal tunnel syndrome and vitamin B-6 therapy. In: Vitamin B-6: its role in health and disease. New York: Alan R. Liss, Inc.; 1985. p. 459-62.
66. Ellis J, Folkers K, Watanabe T, Kaji M, Saji S, Caldwell JW, Temple CA, Wood FS. Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome. Am J Clin Nutr. 1979;32:2040-6.
67. Mitwalli A, Blair G, Oreopoulos DG. Safety of intermediate doses of pyridoxine. Can Med Assoc J. 1984;131:14.
68. Tolis G, Laliberté R, Guyda H, Naftolin F. Ineffectiveness of pyridoxine (B6) to alter secretion of growth hormone and prolactin and absence of therapeutic effects on galactorrhea-amenorrhea syndromes. J Clin Endocrinol Metab. 1977;44:1197-9.
69. Ellis JM. Treatment of carpal tunnel syndrome with vitamin B6. South Med J. 1987;80:882-4.
70. Scientific Committee on FoodOpinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin B6. Brussels: European Commission; 2000. Available from: http://europa.eu.int/comm/food/fs/sc/scf/ out80c_en.pdf.
71. Chen KK, Rose CL, Robbins EB. Toxicity of nicotinic acid. Proc Soc Exp Biol Med. 1938;38:241-5.
72. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77-81.
73. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the tolerable upper intake levels of nicotinic acid and nicotinamide (niacin). Brussels: European Commission; 2002. Available from: http://europa.eu.int/comm/food/fs/sc/scf/out80j_en.pdf.
74. Longnecker MP, Taylor PR, Levander OA, Howe M, Veillon C, McAdam PA, Patterson KY, Holden JM, Stampfer MJ, et al. Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr. 1991;53:1288-94.
75. Yang G, Wang S, Zhou R, Sun S. Endemic selenium intoxication of humans in China. Am J Clin Nutr. 1983;37:872-81.
76. Yang G, Zhou R, Yin S, Gu L, Yan B, Liu Y, Liu Y, Li X. Studies of safe maximum daily dietary selenium intake in a seleniferous area in China. I. Selenium intake and tissue selenium levels of the inhabitants. J Trace Elem Electrolytes Health Dis. 1989;3:77-87.
77. Yang G, Yin S, Zhou R, Gu L, Yan B, Liu Y, Liu Y. Studies of safe maximum daily dietary Se-intake in a seleniferous area in China. II. Relation between SE-intake and the manifestation of clinical signs and certain biochemical alterations in blood and urine. J Trace Elem Electrolytes Health Dis. 1989;3:123-30.
78. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomised controlled trial. JAMA. 1996;276:1957-63.
79. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the tolerable upper intake level of selenium. Brussels: European Commission; 2000. Available from: http://europa.eu.int/comm/food/fs/sc/scf/out80g_en.pdf.
80. Renwick AG, Flynn A, Fletcher RJ, Muller DJG, Tuijtelaars S, Verhagen H. Risk-benefit analysis of micronutrients. Food Chem Toxicol. 2004;42:1903-22.
81. Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol. 2004;43:203-16.
82. Renwick AG, Barlow SM, Hertz-Picciotto I, Boobis AR, Dybing E, Edler L, Eisenbrand G, Greig JB, Kleiner J, et al. Risk characterization of chemicals in food and diet. Food Chem Toxicol. 2003;41:1211-71.